Inflammation therapy
A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB 2 receptor but having substantially no efficacy at the CB 1 receptor at that amount.
1. A method of treating cerebral ischemia/reperfusion injury or spinal cord injury in a patient in need thereof or preventing spinal cord injury in a patient, comprising administering to the patient a therapeutically effective amount of a cannabinoid CB 2 receptor agonist, wherein the agonist is O-1966.
2. The method as claimed in claim 1 , wherein the patient suffers from a disease selected from the group consisting of head trauma, stroke, cerebral bleeds, Alzheimer's and Parkinson's diseases and CNS inflammation in multiple sclerosis.
3. The method as claimed in claim 1 , wherein the agonist is administered in combination with a CB 1 receptor antagonist.
4. A pharmaceutical composition for cerebral ischemia/reperfusion injury or spinal cord injury in a patient in need thereof after the cerebral ischemia/reperfusion injury or spinal cord injury, comprising a therapeutically effective amount of a cannabinoid CB 2 receptor agonist, wherein the agonist is O-1966.